The US FDA has granted accelerated approval to Regeneron's investigational gene therapy Otarmeni (lunsotogene parvec-cwha), making it the first and currently only approved gene therapy for genetic hearing loss, as well as Regeneron's first approved gene therapy. The company said Otarmeni will be provided free of charge in the US.

Otarmeni, formerly known as DB-OTO, is an adeno-associated virus vector-based therapy for children and adults with severe-to-profound or profound sensorineural hearing loss caused by certain OTOF variants. The therapy is designed to deliver a functional OTOF gene copy into the cochlea through a modified nonpathogenic virus, restoring durable physiologic hearing in patients whose inner-ear structures remain intact but who lack functional otoferlin.
The approval was supported by the pivotal CHORD trial. In 20 participants aged 10 months to 16 years who received a single intracochlear infusion, 80% reached the primary endpoint of pure-tone average threshold of 70 dB HL or lower at 24 weeks, and another participant reached that threshold at week 48. A key secondary endpoint was also met, with 70% achieving auditory brainstem response of 90 dB or lower at 24 weeks. Among patients followed for 48 weeks, all prior responders maintained response, and 42% achieved normal hearing sufficient to hear whispers. The most common treatment-related adverse reactions in the safety population included otitis media, vomiting, nausea, vertigo, procedural pain, gait disturbance, and nystagmus.